Establishment Labs Holdings, Inc. (ESTA)

Establishment Labs' stock price has been impacted by quarterly earnings reports and insider trading activity in the past six months. The company reported stronger-than-expected results for Q4 2025, beating both EPS and revenue forecasts, but the stock declined due to investor concerns about future profitability. For Q1 2026, revenue exceeded analyst estimates, but a larger-than-expected loss per share caused the stock to fall. JW Asset Management, LLC, and another insider sold shares in May and April 2026, respectively.

Demand for Establishment Labs' products exhibits seasonality, with the first quarter typically being a seasonally light quarter and the fourth quarter generally the strongest for breast augmentation. Despite Q1 being seasonally light, the company reported quarter-over-quarter growth in its U.S. sales for Q1 2026.

Establishment Labs Holdings, Inc. is a global medical technology company focused on women's health and wellness, particularly breast aesthetics and reconstruction. They design, manufacture, and market silicone gel-filled breast implants under the Motiva Implants brand, along with breast tissue expanders and minimally invasive platforms like Mia Femtech and Preservé. The company's strategy centers on breast health through science, engineering, and technology.

Establishment Labs has a broad international presence, distributing its products through distributors and its direct sales force in Europe, the Middle East, Africa, Latin America, Asia, and the United States. Its manufacturing facilities are located in Costa Rica. The U.S. market is a key growth area, and the company has significant market shares in regions like Switzerland, South Korea, and Taiwan, while expanding in China through a distribution partner.

Establishment Labs has maintained a generally positive brand reputation within the analyst community, with analysts issuing "Buy" ratings. The company emphasizes its "industry-low device-related complication rates" as a key differentiator for its Motiva products. In April 2026, the company announced it had surpassed more than five million Motiva devices in the market. A critical article from October 2022 raised concerns about the independence of some of the company's safety studies and potential conflicts of interest, but no recent events within the past year have negatively impacted the brand reputation.

Establishment Labs has a diverse ownership structure, with institutional shareholders owning approximately 66.93% to 90.06% of the stock. Insiders hold around 18.62% to 19.68% of the shares, while public companies and individual investors own a smaller percentage, ranging from 0.99% to 12.40%. Major institutional owners include JW Asset Management, LLC, RTW Investments, LP, and Brown Advisory Inc. Juan Jose Chacon Quiros and Nicholas Sheridan Lewin are notable insiders.